| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 51 nM (3D7 strain) and 53 nM (Dd2 strain)[1]
The primary target of CWHM-1552 is Plasmodium falciparum, the malaria parasite. The compound inhibits parasite growth through an as-yet-fully-elucidated mechanism. CWHM-1552 shows potent activity against both the 3D7 (drug-sensitive) and Dd2 (drug-resistant) strains. The compound is orally bioactive. |
|---|---|
| ln Vitro |
In vitro studies have demonstrated that CWHM-1552 is an effective P. falciparum inhibitor. Against the 3D7 strain, the IC₅₀ is 51 nM, and against the Dd2 strain, the IC₅₀ is 53 nM. These potent in vitro activities make CWHM-1552 a promising candidate for antimalarial drug development.
|
| ln Vivo |
CWHM-1552 (Compound (-)-32a) suppresses parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day when taken orally for four days[1]. In mice, CWHM-1552 (iv injection; 2 mg/kg/day for 48 hours) had minimal clearance and reasonable half-lives (2.7 h)[1]. In a malarial mouse model, CWHM-1552 exhibits favorable pharmacokinetic characteristics and oral effectiveness. The in vivo ED90 and ED99 of CWHM-1552 are less than 10 mg/kg/day and 30 mg/kg/day, respectively[1].
In vivo studies have shown that oral administration of CWHM-1552 at 30 mg/kg and 10 mg/kg inhibits parasitemia by 99.9% and 94%, respectively. The compound is orally efficacious in mouse models of malaria. These in vivo results demonstrate the compound's potential for further development as an antimalarial agent. |
| Enzyme Assay |
For in vitro activity screening, standard antimalarial assays are used. P. falciparum parasites are cultured in human erythrocytes and treated with serial dilutions of CWHM-1552. Parasite growth is assessed by measuring [³H]-hypoxanthine incorporation or by fluorescence-based methods. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based studies, P. falciparum parasites are cultured in RPMI 1640 medium supplemented with human serum. Parasites are treated with serial dilutions of CWHM-1552, and growth inhibition is assessed. Cytotoxicity against mammalian cells is assessed in parallel. Standard protocols for antimalarial activity screening are described in the literature.
|
| Animal Protocol |
Animal/Disease Models: P. chabaudi ASS infected Mice[1]
Doses: 3, 10, 30 mg/kg Route of Administration: po (oral gavage) daily for 4 days Experimental Results: Inhibited parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day. Animal/Disease Models: Male KM mice[1] Doses: 2 mg/kg Route of Administration: Iv administration; daily Experimental Results: Had respectable half-lives (2.7 h) and low clearance in mice. In vivo animal studies for CWHM-1552 use mouse models of malaria. Mice infected with P. falciparum are treated with CWHM-1552 via oral administration. Parasitemia is monitored by microscopy or flow cytometry. Efficacy endpoints include reduction in parasitemia and survival. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CWHM-1552 have been characterized in preclinical studies. In KM mice, intravenous administration of 2 mg/kg showed a half-life (T1/2) of 2.7 hours and low clearance. The compound is orally bioavailable. Specific PK parameters have been reported in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for CWHM-1552 are limited. As a research compound, standard toxicological studies have not been extensively published. Cytotoxicity against mammalian cell lines has been assessed in vitro. Standard safety assessments would be needed for clinical development.
|
| References |
[1]. Meyers MJ, et al. 4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl) acetamides. ACS Med Chem Lett. 2019 May, 10(6):966-971.
|
| Additional Infomation |
CWHM-1552 is a research compound for antimalarial drug discovery. It is an orally efficacious inhibitor of P. falciparum with potent activity against both drug-sensitive and drug-resistant strains. No clinical trials have been reported. The compound serves as a lead for the development of new antimalarial therapeutics.
|
| Molecular Formula |
C22H27F2N3O
|
|---|---|
| Exact Mass |
387.212
|
| CAS # |
2368253-58-9
|
| PubChem CID |
139593256
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
512
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C1=CC=C(C=C1)[C@@H]2CNC[C@H]2NC(=O)CC3=CC=C(C=C3)N(C)C)(F)F
|
| InChi Key |
WQTOGFREMHSJJS-VQTJNVASSA-N
|
| InChi Code |
InChI=1S/C22H27F2N3O/c1-22(23,24)17-8-6-16(7-9-17)19-13-25-14-20(19)26-21(28)12-15-4-10-18(11-5-15)27(2)3/h4-11,19-20,25H,12-14H2,1-3H3,(H,26,28)/t19-,20+/m0/s1
|
| Chemical Name |
N-[(3S,4R)-4-[4-(1,1-difluoroethyl)phenyl]pyrrolidin-3-yl]-2-[4-(dimethylamino)phenyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
